Cencora scores 82 for management and 83 for moat. The management score rests on a return on invested capital of 12.1% and a gross margin of 4.1% — figures that describe a business turning capital into profit efficiently. The balance sheet carries debt at 3.06x equity, which magnifies both the returns above and the risk beneath them.
The price anchors are built on deliberately conservative assumptions. Growth is modelled at 9.5% a year, below the 10.0% actually measured over the last decade — the model caps growth rather than extrapolating a good run forwards. The exit multiple assumed is 19.1x. That produces an intrinsic value of $209.98, a 10-CAP price of $216.62 and a payback time price of $266.80, with the value zone set at the highest of the three, $266.80. Today's price of $348.71 is 31% above it.
The operating figures describe a business performing at a high level; the price asks for that performance to continue and then some. A margin of safety score of 30 is the measure of how little room that leaves for being wrong.
| Price | $348.71 |
| Market cap | $66.5B |
| P/E ratio | 19.5x |
| Return on invested capital | 12.1% |
| Gross margin | 4.1% |
| Debt to equity | 3.06x |
| Free cash flow yield | 6.7% |
| Growth rate used | 9.5% |
| Growth rate measured | 10.0% |
| Exit multiple assumed | 19.1x |
| Company | Moat | Buy price |
| Cardinal Health (CAH) | 73 | $268.13 |
| Henry Schein (HSIC) | 35 | $52.37 |
| McKesson Corporation (MCK) | 67 | $803.39 |
Every number above is built on assumptions that can be changed. In Moatly you can move the growth rate, the exit multiple and the margin of safety and watch every figure recalculate, so you are testing your own view of Cencora rather than accepting ours.